CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
about
sameAs
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuFocus on adoptive T cell transfer trials in melanomaRemoval of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsAdoptive immunotherapy for cancer: building on successIL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensAdoptive cell transfer: a clinical path to effective cancer immunotherapyTumor-specific Th17-polarized cells eradicate large established melanomaCD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsPhenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcomaBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineSorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Novel immunotherapies for hematologic malignanciesSuppression, subversion and escape: the role of regulatory T cells in cancer progressionAdvances in the treatment of metastatic melanoma: adoptive T-cell therapyIdentification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingIndividual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.T-cell receptor gene therapy--ready to go viral?Immunosuppression associated with chronic inflammation in the tumor microenvironmentCish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceComparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsCancer immunotherapy via dendritic cellsRole of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineRationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapyAdministration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trialHuman melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration
P2860
Q21131200-E39BB0C4-B9D8-4B9A-BE13-4ABD53905BBEQ21328679-47AAF6FB-B2C4-4D83-8CD1-29603DC66307Q24540135-1EDF0DD0-B8D3-4A15-A900-37D6527601A4Q24546258-D04A981A-2759-4C72-9EEE-3F4C056D6C77Q24546362-AE359D1A-8D05-4C31-B7A1-C2A6A08829B3Q24548019-4D470E6D-40B4-442A-BB4A-246B7D40C390Q24596055-35ED8DA9-9E69-45BD-A4A7-E5A7479FE39FQ24629841-CE08BDB1-14C2-4D5E-B0BC-4B5A0E69041EQ24644442-2A1F54FE-4AA6-482B-A321-74B7692A9D51Q24644774-FACB114E-ADC9-4770-8E0A-653CEE8973FDQ24648032-AB122271-72AD-4402-9DB4-215FF94C10A7Q24681974-5CD08087-A990-4F9D-8DFC-7523917BCCBBQ24814867-5ED19C55-E02C-4BEF-8F58-839FEF33CB7EQ26744624-7D669BBA-A879-4592-92E2-A7C3B2C148F2Q26782583-D9EB07C1-C265-4315-8BEC-CF21CB25031DQ27002575-B9FC87C4-96EA-4930-A64C-46F79605D320Q27004436-38315C98-894A-43EA-8B28-21BCBEB092E4Q27026151-A0491DBE-4F12-497D-95D2-E64837350F92Q27027803-A37D9A0F-572A-4B03-9941-138991E5AC68Q27334215-58238A84-6669-4915-87DC-621D6DB78946Q27345402-9A403AFA-C655-4278-9B13-0751742D9BCDQ28081611-5B1483E1-B075-452E-B241-BD82454EB25DQ28083450-40755C40-3639-4984-9C78-E6EFD3ADC4A4Q28269352-A2777146-5527-4866-B24A-8DF5FB12E6E1Q28507643-7470AAB9-FF50-4395-9EF4-AB0EBD7F0EE4Q28731711-B7827DCD-4D20-4CE3-B310-8A4454D54384Q28732041-3CF51017-E4EA-4C75-A3C9-FCB94624C325Q29615444-8685D7FE-20D6-4AC3-9D42-B3FC67D6B0C0Q30357718-F18CA676-8F28-41F3-ACD4-64EC96FE4A69Q30359230-53E8B281-C13F-47B9-843A-32F570D18FC0Q30413827-F7980079-9DF1-438A-8CE4-2DEBF4905E96Q30425914-82C7D0DE-E466-4F0A-835C-7889CBFE3927Q31070048-C9CA88F4-1D49-4EF0-9B02-F86EA7D50A8EQ33261122-7E2B4C92-258D-4B87-BDFA-DE16AEAEF712Q33282703-68FBFC5B-4AE6-45D6-8443-54F8C6BC4669Q33299427-2CED8E77-CAC0-4DFF-89B1-8F03D8C1F7B3Q33530527-DFE3D935-8BBC-4263-A424-89215A2D7C6EQ33593877-2741633A-E9F2-4EFB-B1B3-436D87D09FF4Q33614005-99DB910B-60CF-4752-969C-07BA4EE3AD2CQ33624972-9AF8DE3A-74FB-4D8E-8541-165F27AC00A2
P2860
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
CD8+ T cell immunity against a ...... y occurring T regulatory cells
@nl
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@ast
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@en
type
label
CD8+ T cell immunity against a ...... y occurring T regulatory cells
@nl
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@ast
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@en
prefLabel
CD8+ T cell immunity against a ...... y occurring T regulatory cells
@nl
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@ast
CD8+ T cell immunity against a ...... occurring T regulatory cells.
@en
P2093
P2860
P3181
P1476
CD8+ T cell immunity against a ...... y occurring T regulatory cells
@en
P2093
Akgül Akpinarli
Chi-Chao Chan
Ciriaco A Piccirillo
Deborah R Surman
Douglas C Palmer
Nicholas P Restifo
Paul A Antony
Paul J Speiss
Steven A Rosenberg
Steven E Finkelstein
P2860
P304
P3181
P356
10.4049/JIMMUNOL.174.5.2591
P407
P577
2005-03-01T00:00:00Z